DOD Pancreatic Cancer, Idea Development Award | HT9425 23 PCARP IDA

Opportunity Information: Apply for HT9425 23 PCARP IDA

The Department of Defense Pancreatic Cancer Research Program (PCARP) Idea Development Award is a research funding opportunity intended to push bold, high-risk/high-reward ideas that could open up new directions in pancreatic cancer research and, over time, improve outcomes for patients. The award is aimed at projects that are not simply the next incremental step, but instead are designed to generate impactful new data, uncover important biological or clinical insights, or create new investigative pathways that accelerate progress against pancreatic cancer.

A central expectation of this mechanism is clear potential for impact. Applicants are expected to explain how the proposed work will make an important and original contribution to understanding pancreatic cancer and how it could ultimately translate into better patient outcomes. Even when a project is early-stage and not immediately clinical, the application should still connect the research to meaningful downstream effects on pancreatic cancer research and patient care, spelling out why the idea matters and what it could change.

Innovation is another defining feature. The program is explicitly looking for creativity and a willingness to challenge existing assumptions or propose a new paradigm. Innovation can show up in multiple ways, including a novel study concept, a new or unusually applied method or technology, or a creative adaptation of an existing tool to answer pancreatic cancer questions in a different way. In contrast, proposals that mainly extend previously published work in a straightforward, incremental fashion are not viewed as a good fit for this award.

The program also places unusual emphasis on the research team. At least one team member must bring demonstrated pancreatic cancer research experience, typically evidenced by recent publications and research funding in the field. The inclusion of a biostatistician is encouraged, reflecting the program's interest in strong quantitative design, analysis plans, and overall study rigor. This staffing expectation signals that while the award welcomes risk and novelty, it still expects well-grounded execution and credible interpretation of results.

Although the award supports innovative research, it is not meant for purely speculative concepts without support. Proposals must be based on preliminary data and a solid scientific rationale. Importantly, while the project must be directly relevant to pancreatic cancer, the preliminary data do not have to come from pancreatic cancer studies specifically. Unpublished results from the Principal Investigator(s), team members, or named collaborators may be used, including data generated in other research areas, as long as the application makes a convincing case for why those data justify the pancreatic cancer-focused hypothesis and approach. Applicants are also expected to demonstrate that the rationale is rooted in careful reasoning and a critical review of the existing literature.

A notable option within this opportunity is the Partnering PI pathway designed to support early-career investigators entering or building a career in pancreatic cancer research. Under this approach, an experienced investigator serves as the Initiating PI and acts as a mentor, partnering with an eligible Early-Career Investigator as the Partnering PI. The intent is genuine collaboration plus structured mentorship that strengthens the early-career investigator's trajectory in the field. The Initiating PI typically handles most administrative responsibilities for submission, while both investigators are expected to contribute substantially to the scientific development of the application, including the project narrative and statement of work. If funded, each PI is named on an individual award within the recipient organization. The program also encourages convergence science partnerships, meaning cross-disciplinary collaborations that combine distinct fields, tools, or perspectives to address complex pancreatic cancer problems.

The opportunity is also framed within broader federal priorities around metastatic and advanced cancers. CDMRP encourages applicants to review recommendations from the congressionally mandated Metastatic Cancer Task Force and consider research ideas that align with those recommendations, as long as they also fit the PCARP priorities and the requirements of this specific award mechanism. This emphasis highlights interest in translational and clinically relevant directions, particularly for advanced disease and recurrence, even if individual projects remain preclinical or mechanistic.

Finally, the program strongly encourages collaborations that connect military or Veteran institutions with non-military partners. These partnerships are seen as a way to leverage complementary strengths such as specialized infrastructure, distinct expertise, and access to unique patient populations, with the broader goal of advancing cancer research that matters to Service members, military families, Veterans, and the public.

Administratively, this opportunity was issued by the Department of Defense (Department of the Army, USAMRAA) as a discretionary grant/cooperative agreement program under CFDA 12.420. Eligibility is listed as unrestricted (open to any entity type, subject to any additional eligibility notes in the full announcement). The posting indicates an expected number of awards of around eight, with an original closing date of October 5, 2023, under funding opportunity number HT9425 23 PCARP IDA.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Pancreatic Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 17, 2023.
• Applicants must submit their applications by Oct 05, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 PCARP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: